Navigation Links
BioCryst To Present At 12th Annual BIO CEO & Investor Conference
Date:2/1/2010

BIRMINGHAM, Ala., Feb. 1 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, plans to provide a corporate summary and updates regarding its clinical programs for peramivir, forodesine and BCX4208 at the 12th Annual BIO CEO & Investor Conference in New York on February 8, 2010 at 10:30 a.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at www.biocryst.com.    

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.  BioCryst has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL).  Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians.  For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

SOURCE BioCryst Pharmaceuticals, Inc.

RELATED LINKS
http://www.biocryst.com

'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
2. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
3. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
4. BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
6. BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
7. BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
8. BioCryst Reports Second Quarter 2009 Financial Results And Provides Corporate Update
9. BioCryst Executives to Present at Two Investor Conferences
10. BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S.
11. BioCryst to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 2016 , ... Bluvault ( Bluvault Inc. ) today announced ... clients of Coupa ( Coupa Software ) and other Cloud software, powered by ... component in the suite of innovative implementation services offered by Bluvault. , "Our ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range of benefits ... traditional brokers and health plans. “ The Rapid Emergence of Online Benefits Firms: Strategies ... Services, Inc. (AIS), will offer an accurate picture of online benefits today, and the ...
(Date:5/6/2016)... ... May 06, 2016 , ... The International Yoga Teacher Training schoo ... the island close to the town famous for its sunsets, Oia. This all inclusive ... continue to have an amazing experience in Greece, we just can’t stay away” says ...
(Date:5/6/2016)... ... May 06, 2016 , ... Few events in healthcare ... mostly for its cost despite its potential to wipe out a silent killer, ... of a class called direct-acting antivirals (DAAs)—have created fallout in the courts and ...
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... “ Crossing ... Press) shares accounts of dying patients who have allowed those holding vigil to glimpse ... Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain insight into ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 , First quarter ... revenues of $964 million , First quarter ... $0.40 , Company revises 2016 financial guidance; ... $4.03 billion and 2016 adjusted diluted non-GAAP earnings per share ... Company provides updates regarding Generics business and manufacturing facility restructuring ...
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
Breaking Medicine Technology: